FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAIVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTS

被引：0
|
作者：
Firpi, R. [1 ]
Reau, N. [2 ]
Korner, E. [3 ]
Hoop, R. [3 ]
Han, J. [3 ]
Mangia, A. [4 ]
Ferenci, P. [5 ]
Everson, G. [6 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[5] Med Univ Vienna, Vienna, Austria
[6] Univ Colorado, Denver, CO 80202 USA
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60817-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
815
引用
收藏
页码：S334 / S334
页数：1
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION
    Hezode, C.
    Bruno, S.
    Jacobson, I.
    Serfaty, L.
    Kwo, P.
    Zhou, A.
    Gilbert, C.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S500 - S500
  • [2] Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea
    Wei, Lai
    Han, Tao
    Yang, Dongliang
    Heo, Jeong
    Shang, Jia
    Cheng, Jun
    Chen, Xinyue
    Xie, Qing
    Kim, Ju-Hyun
    Kalmeijer, Ronald
    Ouwerkerk-Mahadevan, Sivi
    Hoeben, Eva
    Lenz, Oliver
    Verbinnen, Thierry
    Sinha, Rekha
    Li, MengChun
    Scott, Jane
    Peeters, Monika
    Witek, James
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) : 912 - 920
  • [3] Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Kumada, Hiromitsu
    Toyota, Joji
    Okanoue, Takeshi
    Chayama, Kazuaki
    Tsubouchi, Hirohito
    Hayashi, Norio
    JOURNAL OF HEPATOLOGY, 2012, 56 (01) : 78 - 84
  • [4] Baseline predictors of null-response to peginterferon (PegIFN) α2a (40KD)/ribavirin (RBV) in treatment-naive patients with chronic hepatitis C (CHC) infected with HCV genotype 1: analysis of data from the multinational PROPHESYS cohorts
    Mangia, Alessandra
    Gervain, Judit
    Remy, Andre Jean
    Habersetzer, Francois
    Brandao-Mello, Carlos E.
    Banyai, Tivadar
    Ancuta, Ioan
    Horban, Andrzej
    Schmitz, Manuela
    Korner, Eli
    Tatsch, Fernando
    HEPATOLOGY, 2012, 56 : 588A - 589A
  • [5] Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1
    Serfaty, Lawrence
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    Picchio, Gaston
    Beumont, Maria
    Marcellin, Patrick
    GUT, 2012, 61 (10) : 1473 - 1480
  • [6] Daclatasvir plus asunaprevir plus beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients
    Everson, Gregory T.
    Sims, Karen D.
    Thuluvath, Paul J.
    Lawitz, Eric
    Hassanein, Tarek
    Rodriguez-Torres, Maribel
    Desta, Tadesse
    Hawkins, Trevor
    Levin, James M.
    Hinestrosa, Federico
    Rustgi, Vinod
    Schwartz, Howard
    Younossi, Zobair
    Webster, Lynn
    Gitlin, Norman
    Eley, Timothy
    Huang, Shu-Pang
    McPhee, Fiona
    Grasela, Dennis M.
    Gardiner, David F.
    LIVER INTERNATIONAL, 2016, 36 (02) : 189 - 197
  • [7] COST-EFFECTIVENESS OF TELAPREVIR WITH PEGINTERFERON AND RIBAVIRIN FOR TREATMENT-NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV OF GENOTYPE 1 IN JAPAN
    Ishida, H.
    Terai, S.
    Sakaida, I
    Inoue, Y.
    VALUE IN HEALTH, 2012, 15 (07) : A328 - A328
  • [8] EFFICACY AND SAFETY OF SOFOSBUVIR AND DACLATASVIR FOR 8 WEEKS IN TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS WITH CHRONIC HCV GENOTYPE 3 INFECTION
    Hezode, Christophe
    Leroy, Vincent
    Rosa, Isabelle
    Pawlotsky, Jean-Michel
    de Ledinghen, Victor
    Bronowicki, Jean-Pierre
    GASTROENTEROLOGY, 2017, 152 (05) : S1099 - S1099
  • [9] Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naive non-cirrhotic patients with chronic HCV Genotype 3 Infection
    Hezode, Christophe
    Leroy, Vincent
    Rosa, Isabelle
    Roudot-Thoraval, Francoise
    Pawlotsky, Jean-Michel
    de Ledinghen, Victor
    Bronowicki, Jean-Pierre
    HEPATOLOGY, 2016, 64 : 953A - 954A
  • [10] Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naive non-cirrhotic patients with chronic HCV Genotype 3 Infection
    Hezode, Christophe
    Leroy, Vincent
    Rosa, Isabelle
    Roudot-Thoraval, Francoise
    Fourati, Slim
    Pawlotsky, Jean-Michel
    de Ledinghen, Victor
    Bronowicki, Jean-Pierre
    HEPATOLOGY, 2017, 66 : 827A - 828A
12345